Protective effect of Rasagiline (cas 136236-51-6) in aminoglycoside ototoxicity
-
Add time:09/03/2019 Source:sciencedirect.com
Sensorineural hearing losses (SNHLs; e.g., ototoxicant- and noise-induced hearing loss or presbycusis) are among the most frequent sensory deficits, but they lack effective drug therapies. The majority of recent therapeutic approaches focused on the trials of antioxidants and reactive oxygen species (ROS) scavengers in SNHLs. The rationale for these studies was the prominent role of disturbed redox homeostasis and the consequent ROS elevation. Although the antioxidant therapies in several animal studies seemed to be promising, clinical trials have failed to fulfill expectations.We investigated the potential of Rasagiline (cas 136236-51-6), an FDA-approved monomanine oxidase type B inhibitor (MAO-B) inhibitor type anti-parkinsonian drug, as an otoprotectant. We showed a dose-dependent alleviation of the kanamycin-induced threshold shifts measured by auditory brainstem response (ABR) in an ototoxicant aminoglycoside antibiotic-based hearing loss model in mice. This effect proved to be statistically significant at a 6-mg/kg (s.c.) dose. The most prominent effect appeared at 16 kHz, which is the hearing sensitivity optimum for mice. The neuroprotective, antiapoptotic and antioxidant effects of rasagiline in animal models, all targeting a specific mechanism of aminoglycoside injury, may explain this otoprotection.The dopaminergic neurotransmission enhancer effect of rasagiline might also contribute to the protection. Dopamine (DA), released from lateral olivocochlear (LOC) fibers, was shown to exert a protective action against excitotoxicity, a pathological factor in the aminoglycoside-induced SNHL. We have shown that rasagiline enhanced the electric stimulation-evoked release of DA from an acute mouse cochlea preparation in a dose-dependent manner. Using inhibitors of voltage-gated Na+-, Ca2+ channels and DA transporters, we revealed that rasagiline potentiated the action potential-evoked release of DA by inhibiting the reuptake.The complex, multifactorial pathomechanism of SNHLs most likely requires drugs acting on multiple targets for effective therapy. Rasagiline, with its multi-target action and favorable adverse effects profile, might be a good candidate for a clinical trial testing the otoprotective indication.
We also recommend Trading Suppliers and Manufacturers of Rasagiline (cas 136236-51-6). Pls Click Website Link as below: cas 136236-51-6 suppliers
Prev:Chemoenzymatic synthesis of Rasagiline (cas 136236-51-6) mesylate using lipases
Next:Short communicationSimultaneous bioanalysis of Rasagiline (cas 136236-51-6) and its major metabolites in human plasma by LC–MS/MS: Application to a clinical pharmacokinetic study) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Regular articleEffect of long-term treatment with Rasagiline (cas 136236-51-6) on cognitive deficits and related molecular cascades in aged mice09/07/2019
- Research ReportRasagiline (cas 136236-51-6) prevents neurodegeneration in thiamine deficient rats—A longitudinal MRI study09/06/2019
- Rasagiline (cas 136236-51-6) in Parkinson's Disease09/05/2019
- Short communicationSimultaneous bioanalysis of Rasagiline (cas 136236-51-6) and its major metabolites in human plasma by LC–MS/MS: Application to a clinical pharmacokinetic study09/04/2019
- Chemoenzymatic synthesis of Rasagiline (cas 136236-51-6) mesylate using lipases09/02/2019
- Original research articleEssential difference between the pharmacological spectrum of (−)-deprenyl and Rasagiline (cas 136236-51-6)09/01/2019
- Case ReportRasagiline (cas 136236-51-6) induced hypersexuality in Parkinson’s disease08/31/2019
- Data articleSynthesis and characterization of 1-pyrindane derivatives as Rasagiline (cas 136236-51-6) analogues08/30/2019
- Rasagiline (cas 136236-51-6) monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan08/29/2019